Kenvue’s CEO Bails as Band-Aids Won’t Fix The Company’s Growth Story… (Shares Rip +6%)

By Stocks News   |   1 year ago   |   Stock Market News
Kenvue’s CEO Bails as Band-Aids Won’t Fix The Company’s Growth Story… (Shares Rip +6%)

Here’s the thing nobody wants to say out loud: when a CEO bails during a “strategic review,” it usually means “we’re screwed in more ways the press release will never admit.” And that’s exactly what we are getting with Kenvue. So, pour one out for Thibaut Mongon, who just yeeted himself out of the top job this Monday. No long goodbye or farewell message… just gone. Like my buddies dad when he went out for milk and never came back. 

(Source: Giphy) 

The company tried to soften the blow by trotting out Kirk Perry, a board member, as interim CEO. Perry’s résumé reads like a LinkedIn wet dream: 23 years at Procter & Gamble, a stint as Google’s ad boss, and most recently CEO of Circana… a.k.a. a firm that sells market data and predictive analytics to brands who want to figure out why millennials won’t buy their sh*t anymore. 

(Source: CNBC) 

But still, the question remains… why? In short, Kenvue is the child Johnson & Johnson cut loose in 2023, probably because J&J figured selling Band-Aids and Listerine was a slower growth story than, say, making your bones regrow in a lab. Kenvue got dumped into public markets with the whole “pure play consumer health” spin, and shocker… turns out consumer health is a bloody knife fight. Activist investors are breathing down Kenvue’s neck because the business, especially the skin and beauty segment (hello, Neutrogena and Aveeno), isn’t printing cash the way everyone pretended it would. Investors want margins. Kenvue’s handing out excuses. 

(Source: AP) 

Whereas now, we have a strategic review. Translation: Strategic review = investment banker bake sale. When a company says “we’re considering all options,” it means they’re on the phone with Centerview and McKinsey asking which brands can be auctioned off to private equity or who can get fired without tanking the stock price. And spoiler alert: Mongon was the sacrificial lamb (for now). The financials tell the real story though. Kenvue’s organic sales fell 4.2% last quarter, and they’re guiding for $0.28 to $0.29 EPS, which…  technically matches Wall Street expectations (but is still limp as hell when inflation and global economic forces are kneecapping everyone’s margins). 

And yet, funny enough, Kenvue stock popped +6% on Mongon’s exit. More specifically, according to our friends at Stocktwits, retail sentiment swung from “bearish” to “neutral,” which is kind of like moving from “hungover and vomiting” to “hungover but functioning enough to scroll TikTok.” Not quite bullish, but hey, it’s progress. The bigger problem for Kenvue though is they’re selling staple consumer goods… Tylenol, Band-Aids, Listerine… that everybody uses but nobody cares two sh*ts about until they’re bleeding or feverish. 

(Source: Giphy) 

It’s not exactly a sexy growth story. You can slap Neutrogena ads all over Instagram, but if the margins suck, Wall Street’s gonna keep side-eyeing your stock all day erryday. Meaning, August 7th may be a circus once Kenvue drops their official Q2 earnings and updates guidance. If they’ve got solid progress on this strategic review… or news of a profitable brand sale, shares could rip. If not, well… expect violence. 

Translation: no matter how many Band-Aids they make, they’re not gonna cover the wounds if this “strategic review” turns into a full-on corporate amputation. In the meantime, keep your eyes on this story and place your bets accordingly, friends. Until next time… 

At the time of publishing, Stocks.News holds positions in Johnson and Johnson and Procter and Gamble as mentioned in the article. 

Did you find this insightful?

Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer